Roche(US:RHHBY) Xin Lang Cai Jing·2026-03-07 21:00Product Development Progress - Roche announced a significant breakthrough in the autoimmune field with its BTK inhibitor Fenebrutinib for treating relapsing multiple sclerosis (RMS), achieving a 51% reduction in annual relapse rate in the Phase III study (FENhance 1) [1] - The company plans to submit a marketing application to global regulatory authorities, potentially making it the first oral medication to cover both RMS and primary progressive multiple sclerosis (PPMS) [1] - In the weight loss sector, Roche aims to be among the top three globally, with its candidate drug CT-388 showing a 22.5% weight reduction over 48 weeks in Phase II clinical trials [1] - Roche will present Phase III supporting data for five new molecular entities (NMEs) in 2026, focusing on unmet needs such as poor responders and muscle loss [1] - The company plans to submit three NMEs for approval in 2026, including giredestrant and vamikibart, and will expand two key indications, concentrating on oncology, neurology, and immunology [1] Financial Performance - Roche's next financial report is expected to be released on July 28, 2026, with the 2025 report showing sales of CHF 61.516 billion, reflecting a 7% growth at constant exchange rates [2] - Core operating profit increased by 13% in 2025 [2] - The company anticipates a high single-digit growth in adjusted earnings per share for 2026, with profit growth expected to outpace sales revenue growth [2]